IL277599A - Use of (1S, 3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid in the treatment of eye disorders - Google Patents
Use of (1S, 3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid in the treatment of eye disordersInfo
- Publication number
- IL277599A IL277599A IL277599A IL27759920A IL277599A IL 277599 A IL277599 A IL 277599A IL 277599 A IL277599 A IL 277599A IL 27759920 A IL27759920 A IL 27759920A IL 277599 A IL277599 A IL 277599A
- Authority
- IL
- Israel
- Prior art keywords
- amino
- carboxylic acid
- difluoromethylenyl
- difluoromethylidene
- cyclopent
- Prior art date
Links
- CBSRETZPFOBWNG-UCORVYFPSA-N (1s,3s)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid Chemical compound N[C@H]1C[C@@H](C(O)=O)CC1=C(F)F CBSRETZPFOBWNG-UCORVYFPSA-N 0.000 title 1
- FBLNZOCTNRXJQD-YFKPBYRVSA-N N[C@H]1C=C(CC1=C(F)F)C(O)=O Chemical compound N[C@H]1C=C(CC1=C(F)F)C(O)=O FBLNZOCTNRXJQD-YFKPBYRVSA-N 0.000 title 1
- 208000030533 eye disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650004P | 2018-03-29 | 2018-03-29 | |
| PCT/US2019/024726 WO2019191525A1 (en) | 2018-03-29 | 2019-03-29 | Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL277599A true IL277599A (en) | 2020-11-30 |
Family
ID=68056529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL277599A IL277599A (en) | 2018-03-29 | 2020-09-24 | Use of (1S, 3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid in the treatment of eye disorders |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20190298674A1 (https=) |
| EP (1) | EP3758693A4 (https=) |
| JP (1) | JP2021519753A (https=) |
| KR (1) | KR20210009306A (https=) |
| CN (1) | CN112218628A (https=) |
| AU (1) | AU2019243586A1 (https=) |
| CA (1) | CA3095468A1 (https=) |
| IL (1) | IL277599A (https=) |
| MX (1) | MX2020010302A (https=) |
| WO (1) | WO2019191525A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR202021080A2 (tr) * | 2020-12-21 | 2022-07-21 | Marmara Ueniversitesi | Thi̇el-behnke kornea di̇strofi̇si̇ (tbkd) i̇çi̇n bi̇r yöntem ve söz konusu yöntem i̇le üreti̇len bi̇r yapay doku i̇skelesi̇ |
| EP4482478A4 (en) * | 2022-02-27 | 2026-03-04 | Univ Northwestern | (3S,4R)-3-AMINO-4-(DIFLUOROMETHYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID AND RELATED COMPOUNDS USED AS SELECTIVE ORNITHIN AMINOTRANSFERASE ACTIVATORS |
| KR20250034134A (ko) * | 2022-07-06 | 2025-03-10 | 오비드 테라퓨틱스 인크. | 암 치료에 있어서 (s)-3-아미노-4-(디플루오로메틸렌일)사이클로펜트-1-엔-1-카르복실산의 사용 |
| US20240285565A1 (en) * | 2023-02-17 | 2024-08-29 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of diabetes and pre-diabetes |
| JP2026506097A (ja) * | 2023-02-17 | 2026-02-20 | オービッド・セラピューティクス・インコーポレイテッド | 多発性硬化症の処置における（ｓ）－３－アミノ－４－（ジフルオロメチレニル）シクロペント－１－エン－１－カルボン酸の使用 |
| US20240285563A1 (en) * | 2023-02-17 | 2024-08-29 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of rheumatoid arthritis |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6794413B1 (en) * | 2002-07-19 | 2004-09-21 | Northwestern University | Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase |
| CA2790820A1 (en) * | 2010-02-25 | 2011-09-01 | Northwestern University | Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor |
| EP2806867A4 (en) * | 2012-01-27 | 2015-09-02 | Catalyst Pharmaceutical Partners Inc | METHOD FOR TREATING TOURETTE SYNDROME WITH GABA AMINO TRANSFERASE INACTIVORS |
| ES2882126T3 (es) * | 2014-11-07 | 2021-12-01 | Univ Northwestern | Inhibición de ornitina aminotransferasa con análogos de GABA para el tratamiento de carcinoma hepatocelular |
| JP6841821B2 (ja) * | 2015-10-09 | 2021-03-10 | ノースウェスタン ユニバーシティ | てんかん、嗜癖および肝細胞癌の処置のためのｇａｂａアミノトランスフェラーゼ不活性化剤としての（ｓ）−３−アミノ−４−（ジフルオロメチレニル）シクロペント−１−エン−１−カルボン酸および関連化合物 |
| US10632088B2 (en) * | 2016-10-10 | 2020-04-28 | Northwestern University | Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria |
| EP4692048A3 (en) * | 2017-02-08 | 2026-04-01 | Ovid Therapeutics Inc. | Methods of treating cdkl5 disorders with the compound ov329 |
| KR20250167147A (ko) * | 2018-02-08 | 2025-11-28 | 오비드 테라퓨틱스 인크. | 이명, 급성 감각신경성 난청, 메니에르병, 투렛 증후군, 주의력 결핍 과잉행동 장애 및 중독의 치료에 있어서 (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 시클로펜탄-1-카르복시산 및 (s)-3-아미노-4-(디플루오로메틸리덴)시클로펜트-1-엔-1-카르복시산의 용도 |
| MX2020012691A (es) * | 2018-05-25 | 2021-02-15 | Univ Northwestern | Proceso para la sintesis del acido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxilico. |
-
2019
- 2019-03-29 JP JP2020552191A patent/JP2021519753A/ja active Pending
- 2019-03-29 CA CA3095468A patent/CA3095468A1/en active Pending
- 2019-03-29 KR KR1020207031345A patent/KR20210009306A/ko not_active Withdrawn
- 2019-03-29 EP EP19777219.7A patent/EP3758693A4/en not_active Withdrawn
- 2019-03-29 US US16/368,907 patent/US20190298674A1/en not_active Abandoned
- 2019-03-29 AU AU2019243586A patent/AU2019243586A1/en not_active Abandoned
- 2019-03-29 MX MX2020010302A patent/MX2020010302A/es unknown
- 2019-03-29 CN CN201980033569.9A patent/CN112218628A/zh active Pending
- 2019-03-29 WO PCT/US2019/024726 patent/WO2019191525A1/en not_active Ceased
-
2020
- 2020-09-24 IL IL277599A patent/IL277599A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020010302A (es) | 2021-01-08 |
| CA3095468A1 (en) | 2019-10-03 |
| CN112218628A (zh) | 2021-01-12 |
| JP2021519753A (ja) | 2021-08-12 |
| AU2019243586A1 (en) | 2020-10-15 |
| EP3758693A1 (en) | 2021-01-06 |
| US20190298674A1 (en) | 2019-10-03 |
| EP3758693A4 (en) | 2021-06-02 |
| WO2019191525A1 (en) | 2019-10-03 |
| KR20210009306A (ko) | 2021-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277599A (en) | Use of (1S, 3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid in the treatment of eye disorders | |
| IL282624A (en) | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders | |
| PL3377637T3 (pl) | Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry | |
| GB201915522D0 (en) | Use of cannabidiol preparations in the treatment of absence epilepsy | |
| EP3215511A4 (en) | Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders | |
| IL304270A (en) | Use of (s)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid and related compounds, (1s, 3s)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and vigabatrin In the treatment of developmental disorders | |
| EP3688021A4 (en) | Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders | |
| ZA202002066B (en) | Compositions and methods for the treatment of eye disorders | |
| ZA202104891B (en) | Liposomial eye drops solution and uses thereof for the treatment of dry eye syndrome | |
| EP3710010A4 (en) | USE OF HM4DI IN TREATMENT OF SEQUENCE DISEASES | |
| EP3644966A4 (en) | TREATMENT AND DIAGNOSIS OF EYE SURFACE DISORDERS | |
| IL274838A (en) | Use of MIR101 or MIR128 in the treatment of seizure disorders | |
| SG11202012473UA (en) | Ophthalmic compositions and methods for the treatment of eye disorders | |
| WO2017129577A8 (en) | Ophthalmic gabapentin for the treatment of corneal ulcers | |
| IL276697A (en) | 3 Beta-(4-methoxybenzyloxy)paragan-5-en-20-one for use in the treatment of cannabinoid-related disorders | |
| LT3897655T (lt) | 3beta-(benziloksi)-17alfa-metil-pregn-5-en-20-onas, skirtas naudoti kognityvinių sutrikimų gydymui | |
| HK40045205A (en) | Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders | |
| EP3661494B8 (en) | Use of tasimelteon for the treatment of affective disorders in majority black african patients | |
| IL280588A (en) | Ophthalmic compositions and methods for treating eye problems and skin diseases | |
| WO2015162552A3 (en) | Composition for topic use | |
| GB201521442D0 (en) | Polytpeptides and analogues thereof for use in the treatment of diabetes and bone disorders | |
| HK40037135A (en) | Use of hm4di in the treatment of seizure disorders | |
| HK40036650A (en) | Use of mir101 or mir128 in the treatment of seizure disorders | |
| HK1233190A1 (en) | Compositions for treating skin conditions | |
| GB201614076D0 (en) | Diagnosis and treatment of ocular disorders |